Originally published as JHC exPRESS on September 6, 2007. doi:10.1369/jhc.7A7270.2007
Volume 55 (12): 1191-1198, 2007 Copyright ©The Histochemical Society, Inc. Hyaluronan in Breast Cancer: Correlations With Nitric Oxide Synthases and Tyrosine Nitrosylation
Department of Pathology, University of Oulu and Oulu University Hospital, Oulu, Finland (PK); Institute of Clinical Medicine, Pathology and Forensic Medicine (YS,V-MK) and Institute of Biomedicine and Anatomy (RT,MT), University of Kuopio, Kuopio, Finland; and Department of Clinical Pathology (YS,V-MK) and Department of Oncology (PA), Kuopio University Hospital, Kuopio, Finland Correspondence to: Peeter Karihtala, Department of Pathology, University of Oulu and Oulu University Hospital, PO Box 5000, FIN-90014, University of Oulu, Oulu, Finland. E-mail: peeter.karihtala{at}oulu.fi
Reactive oxygen species (ROS), including nitric oxide (NO), are associated with all steps of carcinogenesis. Hyaluronan (HA), a high-molecular-mass glycosaminoglycan overexpressed in a variety of human malignancies also has ROS-scavenging properties. We histochemically studied the level of HA in breast carcinoma cells and their stroma and compared it with the expression of NO synthases (NOSs), major antioxidant enzymes, and nitrotyrosine. We also assessed whether the level of HA correlates with traditional prognostic factors of breast cancer and survival. Stromal HA level was moderate or high in all the samples studied (n=185), and 84% of the lesions showed HA-positive carcinoma cells. Intense stromal HA signal was associated with high neuronal NOS expression (p=0.009), whereas tumor-cell associated HA was inversely correlated with nitrotyrosine expression (p=0.027). Of the traditional prognostic factors, tumor cell–associated HA was correlated with poor differentiation (p=0.011), and high stromal HA levels were associated with aggressive features of the carcinomas such as large primary tumor (p=0.002), poor differentiation (p=0.019), and estrogen (p=0.012) and progesterone receptor negativity (p=0.009). High stromal HA level also significantly predicted poorer survival. The strong positive correlation between neuronal NOS and stromal HA could reflect NO-stimulated synthesis of HA, an extracellular matrix alteration that favors breast cancer progression. Furthermore, it is suggested that, while acting as a scavenger of NO-derived radicals, cell-associated HA undergoes partial fragmentation, release from receptors, and further degradation in lysosomes, and thus becomes undetectable in histological sections. (J Histochem Cytochem 55:1191–1198, 2007)
Key Words: antioxidant enzymes hyaluronic acid nitric oxide nitric oxide synthases nitrotyrosine reactive oxygen species
HYALURONAN (HA), or hyaluronic acid, is a ubiquitous, very-high-molecular-mass, linear polysaccharide (up to megadaltons) composed of repeating disaccharide units. It is mainly present in the extracellular matrix and cell surfaces (Laurent and Fraser 1992
As a consequence of aerobic respiration, reactive oxygen species (ROS) are continuously produced in all aerobic organisms. ROS, and especially their subgroup of free radicals, are highly reactive molecules or molecular fragments that play important roles in many physiological processes. However, if the amount of ROS exceeds the capacity of the ROS-suppressing machinery, oxidative stress is said to occur. This imbalance in the redox status is known to damage all cellular macromolecules, including DNA and HA (Wiseman and Halliwell 1996
Nitric oxide (NO) is a short-lived free radical, generated from L-arginine by three NO synthases (NOSs), encoded by three distinct genes. The majority of NO is synthesized by inducible NOS (iNOS), usually after a challenge by immunological or inflammatory stimuli (Nathan and Xie 1994
Despite being a free radical, NO infrequently interacts directly with macromolecules. However, when it reacts with another radical, namely superoxide (O2–), the reaction yields a powerful oxidant, peroxynitrite (ONOO–). ONOO– is one of the most reactive free radicals and is involved in numerous potentially carcinogenic reactions. It is known, for example, to induce transversion mutations and strand breaks in DNA, to trigger lipid peroxidation, to disturb the mitochondrial respiratory chain, and to influence protein phosphorylation by nitrating tyrosine residues of proteins such as p53 (Haddad et al. 1993
Antioxidant enzymes and related redox modulator proteins are the most important system to regulate redox homeostasis of tissues and to protect genome and other critical components against oxidative stress. Superoxide dismutases (SODs) act as a first line to catalyze the reaction of two superoxide anions and two protons to form hydrogen peroxide (H2O2), which still is a reactive molecule. In the light of knockout studies and other experimental studies, manganese SOD (MnSOD) is considered the most important SOD (Li et al. 1995a Because HA may act as an antioxidant in cancer cells, apart from its invasion and metastasis-promoting actions, it is possible to hypothesize that this molecule could act in conjunction with other antioxidant systems in breast cancer cells and thus offer additional evidence of the role of HA expression in cancer promotion. The purpose of this study was to determine whether HA expression in stroma or in malignant cells correlates with NO production, nitrotyrosine, or main antioxidant enzymes in breast carcinoma.
Study Materials A total of 185 invasive breast cancer lesions, originating between 1982 and 2001, were collected from the files of the Department of Pathology, University of Oulu. The material used was a randomly selected subgroup of the blocks that have been used in our two previous studies assessing the role of Prxs, catalase, MnSOD, NOSs, and nitrotyrosine in breast carcinomas. These immunostainings were evaluated and reported previously (Karihtala et al. 2003
The histological diagnosis and grading of the 185 cases studied was assessed according to the criteria of the World Health Organization (Tavassoli and Devilee 2003
Immunohistochemistry
The expression of HA was studied using biotinylated HA binding complex (bHABC) prepared from bovine articular cartilage as described previously (Tammi et al. 1994 The histochemical staining of HA in cells was evaluated as a percentage of all stained malignant cells in the samples. The percentage indicates the proportion of malignant cells expressing HA in the cytoplasm, cellular membranes, or nucleus. When comparing HA staining in carcinoma cells with other stainings, clinicopathological parameters, patient survival, and cell differentiation, these results were divided into two groups according to the median percentage of positively stained cells: 0 = positive staining in 0–39% of carcinoma cells and 1 = positive staining in 40–100% of carcinoma cells. HA staining in the stroma was divided into three groups according to the amount of strong HA expression: – = no strong stromal HA staining present; + = less than one half of the stroma showing strong HA staining; and ++ = more than one half of the stroma showing strong HA staining. The staining results of Prxs I–VI were evaluated semiquantitatively by dividing the intensity of the staining in tumor cells into four different categories: – = no staining present; + = weak staining; + + = moderate staining; and + + + = strong staining. Tumor cell–associated expression of NOSs, nitrotyrosine, MnSOD, and catalase was subclassified into three categories: – = no immunostaining present, + = weak immunostaining; and ++ = strong immunostaining. Estrogen and progesterone receptor status was also based on immunohistochemistry (10% cut-off level for the hormone receptor–negative and –positive groups). From estrogen receptors, molecular form alpha was assessed.
Statistical Analysis
The staining of HA was assessed separately in stromal tissue and in the carcinoma cells. HA level was at least moderate in the stroma of all the lesions studied: 32 (17.3%) were rated moderately positive, and 153 (82.7%) showed strong staining (Figure 1 ). When examining cancer cell–associated HA, we found that 30 (16.2%) of the samples were completely negative and 155 (83.8%) were at least weakly positive. The median percentage for HA-positive carcinoma cells was 40%. There was a very strong association between HA in the stroma and HA in malignant cells (p=2.15 x 10–7). The detailed description of the immunostaining results of Prxs, MnSOD, catalase, NOSs, and nitrotyrosine are found in the references (Karihtala et al. 2003
When we compared the results to traditional prognostic factors, high stromal HA staining was associated with large primary tumor size (p=0.002), estrogen receptor negativity (p=0.021), progesterone receptor negativity (p=0.01), and higher histological grade (p=0.019) (Table 2 ). High levels of HA in carcinoma cells were also correlated with an aggressive histological grade (p=0.011). No grade I tumors expressed HA in carcinoma cells. Thirty-six grade II tumors and 32 grade III tumors were negative for carcinoma cell–associated HA. The corresponding distribution for samples showing carcinoma cell–associated HA were 9 samples of grade I, 36 samples of grade II, and 32 samples of grade III tumors. Despite an obvious trend, the association between large tumor size and high carcinoma cell–associated HA staining was not statistically significant (p=0.087).
Intensive HA signal in the stroma was associated with high nNOS (p=0.009) expression in cancer cells. The expression levels of catalase, Prxs, or MnSOD did not correlate significantly with either stromal HA or HA in cancer cells. However, catalase had an obvious trend to higher expression in tumors with high stromal HA levels (p=0.069). There was a significant inverse correlation between nitrotyrosine and carcinoma cell–associated HA (p=0.027). In Kaplan-Meier analysis, stromal HA positivity predicted shorter survival according to the Breslow (p=0.041) and Tarone-Ware (p=0.043) tests but not according to the log-rank test (p=0.075; Figure 2 ).
The tumor promotion by HA may be mediated in several ways. First, accumulation of HA creates highly hydrated, gel-filled spaces in extracellular matrices. The formation of this less dense matrix separates collagen layers apart and enhances tumor cell migration and penetration through physical barriers in the matrices (Knudson et al. 1984
Four studies using clinical samples from invasive breast carcinomas have previously reported a link between elevated HA levels and poor differentiation, high occurrence of local lymph node metastases, and large primary tumor sizes (Auvinen et al. 1997
In this study, HA expression showed moderate to high expression levels in the stroma, and cancer cell–associated HA was found in 81% of the lesions. Consistent with previous studies from different human carcinomas (Ropponen et al. 1998
Estrogen and progesterone receptor expressions are powerful prognostic factors and form an authoritative criterion for the choice of treatment. In line with our previous study (Auvinen et al. 2000
In the light of current literature, the main antioxidant function of HA is based on degradation of hydroxyl radical and ONOO–, which are considered the two most noxious free radicals (Campo et al. 2004
The inverse correlation between cancer cell–associated HA and nitrotyrosine may reflect the ability of free radicals to cleave HA chains. HA is largely retained in tissues by multivalent binding to cell surface receptors (Lesley et al. 2000
The positive correlation between stromal HA and nNOS expression favors the idea that NO stimulates the synthesis of stromal HA in cancer, such as previously shown in articular cartilage (Hashimoto et al. 2006
It may seem paradoxical that HA, by protecting tumor cells from oxidative stress that is clearly procarcinogenic, still acts as a promoter of carcinogenesis. However, cell redox state-regulating proteins, including antioxidant enzymes, have a general tendency to be upregulated in carcinomas (Gasdaska et al. 1994 In conclusion, the interplay between NO, ROS, and HA seems important in the oxidative stress that initiates and promotes malignant growth. These results are in line with previous reports on the association between HA in tumor stroma and adverse prognosis and suggest a novel "buffering" role of cell-associated HA against excessive oxidative stress that could otherwise lead to apoptosis of the malignant cells. Furthermore, NO may have a role in stimulating the HA synthesis that leads to its stromal accumulation, and at the same time, fragmenting the cell-associated HA into sizes that support tumor angiogenesis.
Received for publication May 2, 2007; accepted July 20, 2007
Ågren UM, Tammi RH, Tammi MI (1997) Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic Biol Med 23:996–1001[CrossRef][Medline] Auvinen P, Tammi R, Parkkinen J, Tammi M, Ågren U, Johansson R, Hirvikoski P, et al. (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156:529–536 Auvinen PK, Parkkinen JJ, Johansson RT, Ågren UM, Tammi RH, Eskelinen MJ, Kosma VM (1997) Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 74:477–481[CrossRef][Medline] Brown NS, Bicknell R (2001) Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3:323–327[CrossRef][Medline] Cadenas E (2004) Mitochondrial free radical production and cell signalling. Mol Aspects Med 25:17–26[CrossRef][Medline] Campo GM, Avenoso A, Campo S, D'Ascola A, Ferlazzo AM, Calatroni A (2004) Reduction of DNA fragmentation and hydroxyl radical production by hyaluronic acid and chondroitin-4-sulphate in iron plus ascorbate-induced oxidative stress in fibroblast cultures. Free Radic Res 38:601–611[CrossRef][Medline] Chazotte-Aubert L, Hainaut P, Ohshima H (2000) Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. Biochem Biophys Res Commun 267:609–613[CrossRef][Medline] Chenevier-Gobeaux C, Morin-Robinet S, Lemarechal H, Poiraudeau S, Ekindjian JC, Borderie D (2004) Effects of pro- and anti-inflammatory cytokines and nitric oxide donors on hyaluronic acid synthesis by synovial cells from patients with rheumatoid arthritis. Clin Sci (Lond) 107:291–296[Medline] Corte MD, Gonzalez LO, Lamelas ML, Alvarez A, Junquera S, Allende MT, Garcia-Muniz JL, et al. (2006) Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treat 97:329–337[CrossRef][Medline] Davis KL, Martin E, Turko IV, Murad F (2001) Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 41:203–236[CrossRef][Medline] Day AJ, de la Motte CA (2005) Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol 26:637–643[CrossRef][Medline] Delmage JM, Powars DR, Jaynes PK, Allerton SE (1986) The selective suppression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci 16:303–310[Abstract] Elston CW, Ellis IO (1998) Classification of malignant breast disease. In Elston CW, Ellis IO, eds. The Breast Systemic Pathology, vol. 13. Edinburgh, Churchill Livingstone, 239–247 Fjeldstad K, Kolset SO (2005) Decreasing the metastatic potential in cancers—targeting the heparan sulfate proteoglycans. Curr Drug Targets 6:665–682[CrossRef][Medline] Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB (2003) Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 106:438–445[CrossRef][Medline] Fraser JR, Laurent TC, Laurent UB (1997) Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242:27–33[CrossRef][Medline] Fukuda K, Takayama M, Ueno M, Oh M, Asada S, Kumano F, Tanaka S (1997) Hyaluronic acid inhibits interleukin-1-induced superoxide anion in bovine chondrocytes. Inflamm Res 46:114–117[CrossRef][Medline] Gasdaska PY, Oblong JE, Cotgreave IA, Powis G (1994) The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1218:292–296[Medline] Götte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233–10237 Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, et al. (2000) Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31:475–481[CrossRef][Medline] Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S (1993) Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 265:555–564 Hashimoto K, Fukuda K, Yamazaki K, Yamamoto N, Matsushita T, Hayakawa S, Munakata H, et al. (2006) Hypoxia-induced hyaluronan synthesis by articular chondrocytes: the role of nitric oxide. Inflamm Res 55:72–77[CrossRef][Medline] Heldin P, De La Torre M, Ytterberg D, Bergh J (1996) Differential synthesis and binding of hyaluronan by human breast cancer cell lines expressing different forms of CD44: relationship to hormone receptor status. Oncol Rep 3:1011–1016 Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, et al. (2002) Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 62:6410–6413 Huie RE, Padmaja S (1993) The reaction of no with superoxide. Free Radic Res Commun 18:195–199[Medline] Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, Homgren A, et al. (2001) Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95:198–204[CrossRef][Medline] Kalaci A, Yilmaz HR, Aslan B, Sogut S, Yanat AN, Uz E (2007) Effects of hyaluronan on nitric oxide levels and superoxide dismutase activities in synovial fluid in knee osteoarthritis. Clin Rheumatol 25:1306–1311 Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K (2005) Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clin Rheumatol 24:497–501[CrossRef][Medline] Karihtala P, Kinnula VL, Soini Y (2004) Antioxidative response for nitric oxide production in breast carcinoma. Oncol Rep 12:755–759[Medline] Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9:3418–3424 Karihtala P, Winqvist R, Syväoja JE, Kinnula VL, Soini Y (2006) Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur J Cancer 42:2653–2659[CrossRef][Medline] Kinnula VL, Crapo JD (2004) Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 36:718–744[CrossRef][Medline] Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, Stevenson DE, et al. (1998) The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106(suppl 1):289–295[CrossRef][Medline] Knudson W, Biswas C, Toole BP (1984) Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 81:6767–6771 Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, et al. (2007) Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol 170:1086–1099 Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6:2397–2404[Abstract] Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, Säily M, et al. (2004) Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111:514–521[CrossRef][Medline] Lesley J, Hascall VC, Tammi M, Hyman R (2000) Hyaluronan binding by cell surface CD44. J Biol Chem 275:26967–26975 Li JJ, Oberley LW, St Clair DK, Ridnour LA, Oberley TD (1995b) Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 10:1989–2000[Medline] Li Y, Huang T-T, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, et al. (1995a) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11:376–381[CrossRef][Medline] Li Y, Li L, Brown TJ, Heldin P (2007) Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 120:2557–2567[CrossRef][Medline] Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23:2425–2433[Medline] Lipponen P, Aaltomaa S, Tammi R, Tammi M, Ågren U, Kosma V-M (2001) High stromal hyaluronan is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37:849–856[CrossRef][Medline] Llaneza A, Vizoso F, Rodriguez JC, Raigoso P, Garcia-Muniz JL, Allende MT, Garcia-Moran M (2000) Hyaluronic acid as prognostic marker in resectable colorectal cancer. Br J Surg 87:1690–1696[CrossRef][Medline] Nathan C, Xie QW (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725–13728 Paiva P, Van Damme MP, Tellbach M, Jones RL, Jobling T, Salamonsen LA (2005) Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol 98:193–202[CrossRef][Medline] Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB (2003) Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 63:2638–2644 Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A (2001) Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 30:463–488[CrossRef][Medline] Radi R, Rodriguez M, Castro L, Telleri R (1994) Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 308:89–95[CrossRef][Medline] Ricciardelli C, Russell DL, Ween MP, Suwiwat S, Byers S, Marshall VR, Tilley WD, et al. (2007) Formation of hyaluronan-and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 282:10814–10825 Rooney P, Kumar S, Ponting J, Wang M (1995) The role of hyaluronan in tumour neovascularization (review). Int J Cancer 60:632–636[Medline] Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Ågren U, et al. (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58:342–347 Setälä LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Ågren UM, Parkkinen J, et al. (1999) Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 79:1133–1138[CrossRef][Medline] Soini Y, Vakkala M, Kahlos K, Pääkkö P, Kinnula V (2001) MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast epithelial cells. J Pathol 195:156–162[CrossRef][Medline] Soltes L, Mendichi R, Kogan G, Schiller J, Stankovska M, Arnhold J (2006) Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 7:659–668[CrossRef][Medline] Stern R (2005) Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) 53:372–382[Medline] Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, et al. (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10:2491–2498 Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51:794–798 Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D (2001) Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res 19:500–503[CrossRef][Medline] Tammi R, Ågren UM, Tuhkanen AL, Tammi M (1994) Hyaluronan metabolism in skin. Prog Histochem Cytochem 29:1–81[Medline] Tavassoli FA, Devilee P, eds (2003) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, IARC Press Toole BP (2002) Hyaluronan promotes the malignant phenotype. Glycobiology 12:37R–42R Toyokuni S, Okamoto K, Yodoi J, Hiai H (1995) Persistent oxidative stress in cancer. FEBS Lett 358:1–3[CrossRef][Medline] Vizoso FJ, del Casar JM, Corte MD, Garcia I, Corte MG, Alvarez A, Garcia-Muniz JL (2004) Significance of cytosolic hyaluronan levels in gastric cancer. Eur J Surg Oncol 30:318–324[CrossRef][Medline] Wernicke M, Pineiro LC, Caramutti D, Dorn VG, Raffo MM, Guixa HG, Telenta M, et al. (2003) Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol 16:99–107[CrossRef][Medline] Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313:17–29[Medline] Yoshihara S, Kon A, Kudo D, Nakazawa H, Kakizaki I, Sasaki M, Endo M, et al. (2005) A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett 579:2722–2726[CrossRef][Medline]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||